12/30/2025
"Having a blood test that detects a signal for a cancer in somebody with no symptoms and then seeing it confirmed on imaging? It’s a game-changer. It’s completely revolutionary." - Nima Nabavizadeh, MD, Chief medical officer for the OHSU Knight Cancer Institute's Cancer Early Detection Advanced Research Center, or CEDAR.
Dr. Nabavizadeh is the principal investigator for the PATHFINDER 2 study, the largest interventional multi-cancer early detection, or MCED, trial in North America examining the safety and efficacy of Grail’s Galleri MCED blood test to screen for cancers.
OHSU radiation oncologist presents promising study findings, launches a third, Medicare-backed study.